Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled. We hypothesize that in patients with extrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.

NCT Number	NCT06440993
Lead Sponsor	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Collaborators: Universitätsklinikum Düsseldorf, Germany, Universitätsklinikum Köln, AstraZeneca
Conditions	Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
Enrollment	42 participants
Start Date	2024-08-23
Primary Completion	2027-01 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2025-12-01